Diality Funding: How Much Did They Raise & Key Investors

How Much Did Diality Raise?
Funding & Key Investors

Diality, a medical device company focused on revolutionizing kidney disease care, has secured significant capital, with its total funding reaching $74.9M. The company recently announced a major strategic investment of $28M, underscoring its progress in developing versatile hemodialysis solutions. This latest financing round signifies a critical juncture for Diality as it aims to expand its reach and impact in the healthcare sector.

The company's trajectory, marked by a series of funding rounds including a Series A in November 2019 and a Series B in March 2022, highlights a consistent drive for growth and innovation in the nephrology space.

What is Diality?

Diality

Manufacturing

Medical Devices & Equipment

Diality is a privately held medical device company dedicated to transforming the management of kidney disease. The company is actively developing a versatile hemodialysis machine designed for flexible use in various settings, including homes, nursing homes, hospitals, and specialized dialysis centers. Diality's mission is to empower patients and healthcare providers with advanced solutions that improve the quality of life for individuals with kidney disease, offering physicians the adaptability to tailor dialysis treatments to individual patient needs, irrespective of the care environment. This focus on patient-centric innovation positions Diality as a key player in the evolving landscape of renal care.

How much funding has Diality raised?

Diality has raised a total of $74.8M across 4 funding rounds:

2019

Series A

$10M

2020

Debt

$350K

2022

Series B

$36.5M

2023

Other Financing Round

$28M

Series A (2019): $10M, investors not publicly disclosed

Debt (2020): $350K led by PPP

Series B (2022): $36.5M, investors not publicly disclosed

Other Financing Round (2023): $28M, investors not publicly disclosed

What's next for Diality?

With the recent infusion of major strategic capital, Diality is poised for accelerated development and market penetration. The enterprise-level funding suggests a focus on scaling production, expanding clinical trials, and potentially preparing for broader commercialization. The company's strategic objective is likely to establish its innovative hemodialysis system as a leading alternative to traditional treatment methods, thereby enhancing patient autonomy and improving healthcare economics. Future endeavors may include strategic partnerships with healthcare systems and further technological advancements to solidify its market position in the competitive medical device industry.

See full Diality company page

See More Financial Insights